10-KPeriod: FY2023

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2023

Filed February 13, 2024For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed its 2023 Annual Report, detailing a year characterized by strategic adjustments and a focus on its core therapeutic areas. The company has continued its efforts in research and development to bolster its pipeline and navigate patent cliffs. Investors should pay close attention to the company's progress in key therapeutic areas, particularly in oncology and immunology, where significant R&D investments are being made. The report also highlights ongoing efforts in portfolio management, including potential acquisitions, divestitures, and licensing agreements, aimed at optimizing its product mix and long-term growth trajectory. Financial performance for 2023 reflects the company's ongoing strategies, with the Management's Discussion and Analysis providing a deeper dive into revenue drivers, cost management, and cash flow generation. The company's commitment to innovation remains a central theme, underscoring the importance of its R&D pipeline in driving future revenue and maintaining competitive advantage in the dynamic pharmaceutical landscape. Investors are encouraged to review the risk factors section, which outlines potential challenges and uncertainties impacting the business.

Financial Highlights

57 data points
Beta

Revenue

$45.01B

76.2% Gross Margin

Net Income

$8.03B

17.8% Net Margin

EPS (Diluted)

$3.86

Total Assets

$95.16B

Cash & Equivalents

$11.52B

Free Cash Flow

$12.65B

Financial Statements
Beta
Revenue$45.01B
Cost of Revenue$10.69B
Gross Profit$34.31B
R&D Expenses$9.30B
SG&A Expenses$7.77B
Operating Expenses$36.57B
Interest Expense$1.17B
Net Income$8.03B
EPS (Basic)$3.88
EPS (Diluted)$3.86
Shares Outstanding (Basic)2.07B
Shares Outstanding (Diluted)2.08B

Key Highlights

  • 1The report details BMY's ongoing strategic focus on key therapeutic areas including oncology, immunology, cardiovascular, and fibrosis.
  • 2Significant emphasis is placed on research and development activities, with the company investing in its pipeline to drive future growth and address unmet medical needs.
  • 3The company is actively engaged in portfolio management, exploring acquisitions, divestitures, and licensing to optimize its product offerings and market position.
  • 4Management's Discussion and Analysis (MD&A) provides insights into the financial performance, operational strategies, and the company's outlook.
  • 5The filing outlines the competitive landscape and pricing pressures within the pharmaceutical industry, which are key considerations for investors.
  • 6Information on human capital management and resources is included, highlighting the importance of talent in driving innovation and execution.
  • 7Risk factors section details potential challenges such as patent expirations, regulatory changes, and competitive pressures.

Frequently Asked Questions

Bristol Myers Squibb's primary therapeutic areas of focus are oncology, immunology, cardiovascular diseases, and fibrosis, with significant investment in research and development across these segments.

BMY is actively managing its product pipeline through continued R&D investments and exploring strategic licensing arrangements. The company also focuses on product exclusivity and navigating patent expirations to sustain its market position.

Investors should review the Consolidated Statements of Earnings, Balance Sheets, and Cash Flows for an understanding of financial health. The Management's Discussion and Analysis section is crucial for insights into revenue drivers, cost management, and the company's financial strategy and outlook.

Key risks highlighted include patent expirations and loss of market exclusivity for key products, increasing competition, pricing pressures, government regulation, cybersecurity threats, and challenges in drug development and clinical trials.